Zoeken
Algemene medische oncologie

Klinische studies Genito-urinaire tumoren (nier, blaas, urinewegen, prostaat, penis en testis)

Op deze pagina

Planned

BAY 22049 / PANTHA

A Phase 1 open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of 225Ac-PSMA-Trillium in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)

  • Principal investigator : Prof. Dr. H. Dumez
  • Sponsor : Bayer
  • More information : NCT06217822
  • Indication : advanced metastatic castration-resistant prostate cancer (mCRPC)
  • Internal reference number : S71199

CA259-0001

A Phase 1, Multicenter, Open-label Study of BMS-986527, Healthy Donor Allogeneic CD70-targeted Chimeric Antigen Receptor (CAR) T Cells, as Monotherapy or in Combination with an Immuno-oncology Agent (Nivolumab) or Tyrosine Kinase Inhibitor (Cabozantinib) in Participants with Clear Cell Renal Cell Carcinoma (ccRCC)

ProstACT - TLX591-203

A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination with Standard of Care Versus Standard of Care Alone in Patients with Prostate-Specific Membrane Antigen (PSMA) Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Androgen Receptor Pathway Inhibitor (ARPI) Treatment

  • Principal investigator : Prof. Dr. H. Dumez
  • Sponsor : Telix Pharmaceuticals
  • More information : NCT06520345
  • Indication :
  • Internal reference number : S72111

TROPION-Urothelial03 - DS1062-328

A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who progressed during or after Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03) 

  • Principal investigator : Prof. Dr. H. Dumez
  • Sponsor : Daiichi Sankyo
  • More information : NCT07129993
  • Indication : Urothelial Carcinoma
  • Internal reference number : s71361

Ongoing

BET-PSMA-121

An open-label, multicentre, integrated Phase 1 & 2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of Lutetium (177Lu) rhPSMA-10.1 injection in men with metastatic castrate-resistant prostate cancer

  • Principal investigator : Prof. Dr. H. Dumez
  • Sponsor : Blue Earth Therapeutics Ltd
  • More information : NCT05413850
  • Indication : 
  • Internal reference number : s67317

LITESPARK-033 (MK6482-033)

Phase 3, Randomized, Open-Label study of MK-6482 (Belzutifan)+Zanzalintinib vs. Cabozantinib for the Treatment of Participants with Locally advanced or Metastatic RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy

MK6482-043

MK6482-043 is an Open Label Phase III Extension Study for patients with Advanced Solid Tumors or VHL-related neoplasms who have participated in belzutifan trials.

  • Principal investigator : Prof. Dr. Benoit Beuselinck
  • Sponsor :  Merck
  • More information :
  • Indication :
  • Internal reference number : s71548

PRIAM - N22APC

A Phase 2 clinical study to assess efficacy of induction carboplatin/paclitaxel + pembrolizumab for locoregionally advanced penile cancer: PRIAM

  • Principal investigator : Prof. Dr. H. Dumez
  • Sponsor : Nederlands Kanker Instituut AVL
  • More information : NCT06353906
  • Indication : 
  • Internal reference number : s69611

XAlience  (20230239)

A Phase3, Open-label, Multicenter, Randomized Study of Xaluritamig Monotherapy, Xaluritamig Plus Abiraterone versus Investigator's Choise in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  • Principal investigator : Prof. Dr. H. Dumez
  • Sponsor : Amgen
  • More information : NCT07213674
  • Indication : Prostate Cancer
  • Internal reference number : s70847

XmAb819-01 (2281/0141)

Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®30819 in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma (ccRCC)

Laatste aanpassing: 24 juni 2026